Company Encyclopedia
View More
name
Intensity Therapeutics
INTS.US
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
1.930 T
INTS.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Intensity Therapeutics, Inc. granted 180-day extension by Nasdaq to meet bid price requirement. Nasdaq symbol: INTS.

    On December 5, 2025, in Shelton, Connecticut, Intensity Therapeutics, Inc. (Nasdaq: INTS), a prominent late-stage clinical biotechnology firm, announced its dedication to discovering and developing innovative intratumoral cancer treatments. The company is focused on creating therapies that can effectively eradicate tumors.

    Unusual Whales·
    US
    INTS
    +10.80%
    Unusual Whales·
    US
    INTS
    +10.80%

    Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement | INTS Stock News

    Intensity Therapeutics has been granted a 180-day extension by Nasdaq to meet the minimum $1.00 bid price requirement for continued listing. The company must maintain this bid price for ten consecutive business days by June 1, 2026. The extension does not affect the current trading of INTS shares on Nasdaq.

    StockTitan·
    US
    INTS
    +10.80%
    StockTitan·
    US
    INTS
    +10.80%

    Intensity Therapeutics Expands At-The-Market Offering

    Intensity Therapeutics, Inc. announced an increase in its 'at-the-market' offering program to $30 million, enhancing financial flexibility. This expansion allows efficient capital access without obligation to issue shares, depending on market conditions and strategic priorities. Analysts rate INTS stock as a Buy with a $5.00 price target, while Spark's AI Analyst views it as Underperform due to financial challenges typical of pre-revenue biotech firms.

    Tip Ranks·
    US
    INTS
    +10.80%
    Tip Ranks·
    US
    INTS
    +10.80%

    Intensity Therapeutics to present at the 2025 San Antonio Breast Cancer Symposium, focused on cancer therapies.

    On December 4, 2025, in Shelton, Connecticut, Intensity Therapeutics, Inc. (Nasdaq: INTS) announced its focus on developing unique cancer treatments through non-covalent, drug-conjugation technology. This late-stage clinical biotechnology company is dedicated to pioneering proprietary therapies.

    Unusual Whales·
    US
    INTS
    +10.80%
    Unusual Whales·
    US
    INTS
    +10.80%

    Intensity Therapeutics Announces Two Presentations At The Upcoming 2025 San Antonio Breast Cancer Symposium

    Dec 4 (Reuters) - Intensity Therapeutics Inc:* INTENSITY THERAPEUTICS ANNOUNCES TWO PRESENTATIONS AT THE UPCOMING 2025 SAN ANTONIO BREAST CANCER SYMPOSIUM Source text: Further company coverage:

    Reuters·
    US
    INTS
    +10.80%
    Reuters·
    US
    INTS
    +10.80%
    © 2025 Longbridge｜Disclaimer